A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib

Clive Stubbs; Antonio D. Bardoli; Mehran Afshar; Sarah Pirrie; Manuela Miscoria; Isabella Wheeley; Emilio Porfiri

doi:10.21873/anticanres.11315

A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib

Clive Stubbs, Antonio D. Bardoli, Mehran Afshar, Sarah Pirrie, Manuela Miscoria, Isabella Wheeley, Emilio Porfiri^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background: Sunitinib is a tyrosine kinase inhibitor (TKI) targeting tumour angiogenesis in patients with advanced renal cell carcinoma (RCC). Currently no universally agreed model exists correlating the expression of angiogenesis markers with the success of treatment. Patients and Methods: We retrospectively analysed archival tissue for 59 RCC patients treated with sunitinib. The expression of angiogenesis markers VEGF-A, VEGFR, PDGFββ, PDGFR, CCND1 and CA9 was assessed by immunohistochemistry (IHC) and correlated with overall survival (OS) and progression-free survival (PFS). Results: The median OS and median PFS of the whole group of patients was 24.6 months (17.3-34.2) and 19.5 months (11-27) respectively. VEGFA was positive in 29% of tumors, whereas VEGFR was expressed in only 12% of tumours. PDGFββ and its receptor were detected in a minority of cases. CCND1 and CA9 were positive in 44% and 60% of cases. Conclusion: The OS and PFS achieved by our patients reflected previous observations seen with sunitinib, but no correlation was found between expression of angiogenesis markers and clinical outcome.

Original language	English
Pages (from-to)	253-259
Number of pages	7
Journal	Anticancer research
Volume	37
Issue number	1
DOIs	https://doi.org/10.21873/anticanres.11315
Publication status	Published - 1 Jan 2017

Keywords

Angiogenesis
CA9
CCND1
Outcome
PDGFR
PDGFββ
Renal cell carcinoma
Sunitinib
Survival
VEGF-A
VEGFR

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.11315

Cite this

@article{bd45b46430f64c83b922a6b9df36cbab,

title = "A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib",

abstract = "Background: Sunitinib is a tyrosine kinase inhibitor (TKI) targeting tumour angiogenesis in patients with advanced renal cell carcinoma (RCC). Currently no universally agreed model exists correlating the expression of angiogenesis markers with the success of treatment. Patients and Methods: We retrospectively analysed archival tissue for 59 RCC patients treated with sunitinib. The expression of angiogenesis markers VEGF-A, VEGFR, PDGFββ, PDGFR, CCND1 and CA9 was assessed by immunohistochemistry (IHC) and correlated with overall survival (OS) and progression-free survival (PFS). Results: The median OS and median PFS of the whole group of patients was 24.6 months (17.3-34.2) and 19.5 months (11-27) respectively. VEGFA was positive in 29% of tumors, whereas VEGFR was expressed in only 12% of tumours. PDGFββ and its receptor were detected in a minority of cases. CCND1 and CA9 were positive in 44% and 60% of cases. Conclusion: The OS and PFS achieved by our patients reflected previous observations seen with sunitinib, but no correlation was found between expression of angiogenesis markers and clinical outcome.",

keywords = "Angiogenesis, CA9, CCND1, Outcome, PDGFR, PDGFββ, Renal cell carcinoma, Sunitinib, Survival, VEGF-A, VEGFR",

author = "Clive Stubbs and Bardoli, {Antonio D.} and Mehran Afshar and Sarah Pirrie and Manuela Miscoria and Isabella Wheeley and Emilio Porfiri",

year = "2017",

month = jan,

day = "1",

doi = "10.21873/anticanres.11315",

language = "English",

volume = "37",

pages = "253--259",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib

AU - Stubbs, Clive

AU - Bardoli, Antonio D.

AU - Afshar, Mehran

AU - Pirrie, Sarah

AU - Miscoria, Manuela

AU - Wheeley, Isabella

AU - Porfiri, Emilio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Sunitinib is a tyrosine kinase inhibitor (TKI) targeting tumour angiogenesis in patients with advanced renal cell carcinoma (RCC). Currently no universally agreed model exists correlating the expression of angiogenesis markers with the success of treatment. Patients and Methods: We retrospectively analysed archival tissue for 59 RCC patients treated with sunitinib. The expression of angiogenesis markers VEGF-A, VEGFR, PDGFββ, PDGFR, CCND1 and CA9 was assessed by immunohistochemistry (IHC) and correlated with overall survival (OS) and progression-free survival (PFS). Results: The median OS and median PFS of the whole group of patients was 24.6 months (17.3-34.2) and 19.5 months (11-27) respectively. VEGFA was positive in 29% of tumors, whereas VEGFR was expressed in only 12% of tumours. PDGFββ and its receptor were detected in a minority of cases. CCND1 and CA9 were positive in 44% and 60% of cases. Conclusion: The OS and PFS achieved by our patients reflected previous observations seen with sunitinib, but no correlation was found between expression of angiogenesis markers and clinical outcome.

AB - Background: Sunitinib is a tyrosine kinase inhibitor (TKI) targeting tumour angiogenesis in patients with advanced renal cell carcinoma (RCC). Currently no universally agreed model exists correlating the expression of angiogenesis markers with the success of treatment. Patients and Methods: We retrospectively analysed archival tissue for 59 RCC patients treated with sunitinib. The expression of angiogenesis markers VEGF-A, VEGFR, PDGFββ, PDGFR, CCND1 and CA9 was assessed by immunohistochemistry (IHC) and correlated with overall survival (OS) and progression-free survival (PFS). Results: The median OS and median PFS of the whole group of patients was 24.6 months (17.3-34.2) and 19.5 months (11-27) respectively. VEGFA was positive in 29% of tumors, whereas VEGFR was expressed in only 12% of tumours. PDGFββ and its receptor were detected in a minority of cases. CCND1 and CA9 were positive in 44% and 60% of cases. Conclusion: The OS and PFS achieved by our patients reflected previous observations seen with sunitinib, but no correlation was found between expression of angiogenesis markers and clinical outcome.

KW - Angiogenesis

KW - CA9

KW - CCND1

KW - Outcome

KW - PDGFR

KW - PDGFββ

KW - Renal cell carcinoma

KW - Sunitinib

KW - Survival

KW - VEGF-A

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=85007551409&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11315

DO - 10.21873/anticanres.11315

M3 - Article

C2 - 28011500

AN - SCOPUS:85007551409

SN - 0250-7005

VL - 37

SP - 253

EP - 259

JO - Anticancer research

JF - Anticancer research

IS - 1

ER -

A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this